Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Rhea-AI Summary

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company will present a fireside chat on October 8, 2024, at 1:30 pm ET.

Investors and interested parties can access the live webcast of the fireside chat through the Arbutus website at https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the company's website for a time after the event. Arbutus will also host one-on-one meetings during the conference.

WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:

H.C. Wainwright 5^th Annual Viral Hepatitis Virtual Conference: Fireside Chat on October 8, 2024 at 1:30 pm ET

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When is Arbutus Biopharma (ABUS) presenting at the H.C. Wainwright Viral Hepatitis Conference?

Arbutus Biopharma (ABUS) is presenting a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024, at 1:30 pm ET.

How can I access the webcast of Arbutus Biopharma's (ABUS) presentation?

You can access the live webcast of Arbutus Biopharma's (ABUS) fireside chat presentation by visiting https://investor.arbutusbio.com/events-presentations.

What is the main focus of Arbutus Biopharma (ABUS)?

Arbutus Biopharma (ABUS) is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection.

Will Arbutus Biopharma (ABUS) be hosting one-on-one meetings at the conference?

Yes, Arbutus Biopharma (ABUS) will be hosting one-on-one meetings at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference.